$CCEL
CRYO CELL INTERNATIONAL INC

2024 Q3 Form 10-Q Financial Statement

#000095017024083637 Filed on July 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $8.067M $8.043M
YoY Change 2.5% 3.48%
Cost Of Revenue $2.126M $2.025M
YoY Change -1.41% -5.53%
Gross Profit $5.941M $6.018M
YoY Change 3.98% 6.9%
Gross Profit Margin 73.65% 74.83%
Selling, General & Admin $4.150M $4.021M
YoY Change 9.07% -0.44%
% of Gross Profit 69.85% 66.82%
Research & Development $193.9K $241.1K
YoY Change -43.65% -20.87%
% of Gross Profit 3.26% 4.01%
Depreciation & Amortization $246.6K $112.2K
YoY Change -27.23% -68.39%
% of Gross Profit 4.15% 1.86%
Operating Expenses $4.344M $4.262M
YoY Change 4.7% -7.37%
Operating Profit $1.390M $1.392M
YoY Change 19.71% 35.37%
Interest Expense $533.5K $329.3K
YoY Change 13.59% -148.17%
% of Operating Profit 38.38% 23.66%
Other Income/Expense, Net -$10.03K $80.66K
YoY Change -89.27% 3796.71%
Pretax Income $1.380M $1.472M
YoY Change 29.25% 324.97%
Income Tax $328.2K $816.4K
% Of Pretax Income 23.78% 55.45%
Net Earnings $1.052M $655.8K
YoY Change 54.53% 196.76%
Net Earnings / Revenue 13.04% 8.15%
Basic Earnings Per Share $0.13 $0.08
Diluted Earnings Per Share $0.13 $0.08
COMMON SHARES
Basic Shares Outstanding 8.062M 8.104M
Diluted Shares Outstanding 8.174M 8.232M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.127M $1.530M
YoY Change 76.14% -9.61%
Cash & Equivalents $197.4K $469.2K
Short-Term Investments $1.929M $1.060M
Other Short-Term Assets $416.5K $435.5K
YoY Change -7.58% -58.9%
Inventory $731.4K $708.2K
Prepaid Expenses $512.5K $651.8K
Receivables $6.874M $6.831M
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.66M $10.16M
YoY Change 7.29% -1.52%
LONG-TERM ASSETS
Property, Plant & Equipment $22.12M $22.16M
YoY Change 17.42% 21.19%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $938.2K $955.2K
YoY Change -32.55% -32.5%
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $30.16M $30.25M
YoY Change -26.49% -17.11%
Total Long-Term Assets $52.27M $52.41M
YoY Change -12.67% -10.32%
TOTAL ASSETS
Total Short-Term Assets $10.66M $10.16M
Total Long-Term Assets $52.27M $52.41M
Total Assets $62.93M $62.57M
YoY Change -9.83% -9.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.001M $1.828M
YoY Change -28.18% -54.94%
Accrued Expenses $2.681M $3.217M
YoY Change 51.06% 31.78%
Deferred Revenue $9.827M $9.581M
YoY Change 1.34% 1.32%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $174.6K $171.6K
YoY Change 7.33% 8.3%
Total Short-Term Liabilities $17.42M $19.45M
YoY Change -6.14% -1.32%
LONG-TERM LIABILITIES
Long-Term Debt $8.331M $8.356M
YoY Change -1.63% -1.76%
Other Long-Term Liabilities $55.07M $53.86M
YoY Change 7.46% 30.09%
Total Long-Term Liabilities $55.07M $53.86M
YoY Change 7.46% 7.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.42M $19.45M
Total Long-Term Liabilities $55.07M $53.86M
Total Liabilities $72.49M $73.31M
YoY Change 3.84% 5.3%
SHAREHOLDERS EQUITY
Retained Earnings -$28.90M -$29.95M
YoY Change 44.7% 45.02%
Common Stock $44.19M $44.05M
YoY Change 1.86% 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.86M $24.84M
YoY Change 6.08% 6.04%
Treasury Stock Shares
Shareholders Equity -$9.559M -$10.74M
YoY Change
Total Liabilities & Shareholders Equity $62.93M $62.57M
YoY Change -9.83% -9.0%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $1.052M $655.8K
YoY Change 54.53% 196.76%
Depreciation, Depletion And Amortization $246.6K $112.2K
YoY Change -27.23% -68.39%
Cash From Operating Activities $2.437M $1.773M
YoY Change 25.48% -10.84%
INVESTING ACTIVITIES
Capital Expenditures $185.7K $1.752M
YoY Change -94.36% 20.21%
Acquisitions
YoY Change
Other Investing Activities -$479.9K -$1.003M
YoY Change 403.83% 753.11%
Cash From Investing Activities -$665.6K -$2.755M
YoY Change -80.34% 74.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.043M 1.203M
YoY Change -326.08% -281.42%
NET CHANGE
Cash From Operating Activities 2.437M 1.773M
Cash From Investing Activities -665.6K -2.755M
Cash From Financing Activities -2.043M 1.203M
Net Change In Cash -271.8K 222.1K
YoY Change -49.68% -189.16%
FREE CASH FLOW
Cash From Operating Activities $2.437M $1.773M
Capital Expenditures $185.7K $1.752M
Free Cash Flow $2.252M $21.56K
YoY Change -266.96% -95.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40767
dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
CCEL
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8061786
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
469195
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406067
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1060436
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
574183
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4026578
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3822300
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6831447
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
651781
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615407
CY2024Q2 us-gaap Inventory Net
InventoryNet
708193
CY2023Q4 us-gaap Inventory Net
InventoryNet
768877
CY2024Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
122113
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
435475
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
389950
CY2024Q2 us-gaap Assets Current
AssetsCurrent
10156527
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9452837
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22161859
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20996883
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
955187
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
989121
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
5198075
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5260119
CY2024Q2 us-gaap Goodwill
Goodwill
1941411
CY2023Q4 us-gaap Goodwill
Goodwill
1941411
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
881744
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
779044
CY2023Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
746493
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30248210
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30771050
CY2024Q2 us-gaap Assets
Assets
62566596
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1827717
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3174584
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3217270
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170809
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
171605
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4222728
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1222728
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
294777
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q2 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
133333
CY2023Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1200000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9580635
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19448065
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20864001
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
43920645
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
35353
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
44226
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
8356372
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672339
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
53859709
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51388001
CY2024Q2 us-gaap Liabilities
Liabilities
73307774
CY2023Q4 us-gaap Liabilities
Liabilities
72252002
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8063786
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8286785
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
148492
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
148492
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43896637
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43411143
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
24839156
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23431685
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29947151
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31159182
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-10741178
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62566596
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61220770
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8042811
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7772690
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15895046
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15597105
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2024750
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2143186
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4185218
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4210550
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4021357
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4038968
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8361002
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7917871
CY2024Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3697
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-23124
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-8873
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-187825
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241085
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
304682
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
743974
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
383516
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
59798
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
281080
us-gaap Depreciation And Amortization
DepreciationAndAmortization
92984
us-gaap Depreciation And Amortization
DepreciationAndAmortization
561924
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
6651293
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
6744792
us-gaap Costs And Expenses
CostsAndExpenses
13682305
us-gaap Costs And Expenses
CostsAndExpenses
12886036
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1391518
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1027898
us-gaap Operating Income Loss
OperatingIncomeLoss
2212741
us-gaap Operating Income Loss
OperatingIncomeLoss
2711069
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
258623
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
10377
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
533594
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6696
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
151175
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
137
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2066
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3334
CY2024Q2 us-gaap Interest Expense
InterestExpense
329273
CY2023Q2 us-gaap Interest Expense
InterestExpense
469952
us-gaap Interest Expense
InterestExpense
585732
us-gaap Interest Expense
InterestExpense
936183
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
80662
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-681483
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53949
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1150127
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1472180
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
346415
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2266690
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1560942
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
816390
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
125439
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1054659
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
573154
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
655790
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
us-gaap Net Income Loss
NetIncomeLoss
1212031
us-gaap Net Income Loss
NetIncomeLoss
987788
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8117479
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8325101
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8197223
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8395307
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8232327
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8331911
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8275414
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8402538
us-gaap Profit Loss
ProfitLoss
1212031
us-gaap Profit Loss
ProfitLoss
987788
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
198264
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
724890
ccel Impairment On Investment
ImpairmentOnInvestment
308000
ccel Impairment On Investment
ImpairmentOnInvestment
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-8873
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-187825
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
533594
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6696
ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
105887
ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
-223974
us-gaap Share Based Compensation
ShareBasedCompensation
485494
us-gaap Share Based Compensation
ShareBasedCompensation
469591
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
560200
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
403040
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10669
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10862
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
151413
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
155617
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
815407
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1041578
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
36374
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
83909
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-122728
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-410993
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
45525
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-17820
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
32551
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
56798
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-599852
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
609687
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1953539
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1369083
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-110508
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-157011
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2609927
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2521664
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1416616
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3633026
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2209654
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1833043
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
933334
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
400000
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
0
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
179306
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
854869
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1082923
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
902210
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
359752
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3095647
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2776908
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1407471
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
791452
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
78370
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
77126
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
200000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3200000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
228000
ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
0
ccel Payment Of Earnout
PaymentOfEarnout
0
ccel Payment Of Earnout
PaymentOfEarnout
67500
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1742159
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1436078
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
63128
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-579960
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
406067
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
469195
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1123998
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
0
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
737867
ccel Construction Costs Payable
ConstructionCostsPayable
-880348
ccel Construction Costs Payable
ConstructionCostsPayable
1841254
us-gaap Interest Paid Net
InterestPaidNet
940697
us-gaap Interest Paid Net
InterestPaidNet
869076
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1952502
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
983647
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10338012
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
178139
CY2024Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1237095
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
655790
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-10741178
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
485494
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1407471
us-gaap Net Income Loss
NetIncomeLoss
1212031
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-10741178
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-687517
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
156417
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
548251
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
469591
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
791452
us-gaap Net Income Loss
NetIncomeLoss
987788
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
53501280
CY2024Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9580635
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2024Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
14441
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
25493
CY2023Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10958
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
21390
CY2024Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
31490
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
61669
CY2023Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
28512
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
54948
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
738555
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6831447
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9580635
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
43920645
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q2 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
61669
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
18809
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
738555
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
21115429
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
20860222
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6831447
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50891353
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
10803662
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
8193735
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
53501280
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
54948
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
16460
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
654116
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
21299426
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
20660888
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6682479
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
13557161
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11035497
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48108050
CY2024Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
485000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
470000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
178000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
157000
CY2023Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
122113
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
151175
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
228000
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at May 31, 2024 and November 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8042811
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7772690
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2024750
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2143186
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1391518
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1027898
CY2024Q2 us-gaap Interest Expense
InterestExpense
329273
CY2023Q2 us-gaap Interest Expense
InterestExpense
469952
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15895046
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15597105
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4185218
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4210550
us-gaap Operating Income Loss
OperatingIncomeLoss
2212741
us-gaap Operating Income Loss
OperatingIncomeLoss
2711069
us-gaap Interest Expense
InterestExpense
585732
us-gaap Interest Expense
InterestExpense
936183
CY2024Q2 us-gaap Assets
Assets
62566596
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q2 ccel Inventory Collection Kits
InventoryCollectionKits
46532
CY2023Q4 ccel Inventory Collection Kits
InventoryCollectionKits
47739
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2024Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5906268
CY2023Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
6028996
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
955187
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
989121
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
228000
CY2024Q2 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.5
ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
8527977
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
171605
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
8356372
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
8527977
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
47166
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
47166
CY2023Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
209624
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
417543
CY2024Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
210700
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
409307
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
655790
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
us-gaap Net Income Loss
NetIncomeLoss
1212031
us-gaap Net Income Loss
NetIncomeLoss
987788
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8117479
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8325101
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8197223
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8395307
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
114848
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6810
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
78191
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7231
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8232327
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8331911
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8275414
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8402538
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
505778
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y1M9D
CY2024Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.14
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
375718
CY2024Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.5
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
114193
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
103000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
87133
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
130060
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.99
CY2011Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6785460
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6562461
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
881744
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
294777
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672339
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
967116
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1077624
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
153381
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
435970
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
458026
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38247
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
118508
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
967116
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M29D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
88743
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
88918
us-gaap Operating Lease Payments
OperatingLeasePayments
178097
us-gaap Operating Lease Payments
OperatingLeasePayments
177313
CY2023Q4 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064

Files In Submission

Name View Source Status
0000950170-24-083637-index-headers.html Edgar Link pending
0000950170-24-083637-index.html Edgar Link pending
0000950170-24-083637.txt Edgar Link pending
0000950170-24-083637-xbrl.zip Edgar Link pending
ccel-20240531.htm Edgar Link pending
ccel-20240531.xsd Edgar Link pending
ccel-ex10_5.htm Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
ccel-20240531_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable